GERON CORPORATION
NASDAQ: GERN (Geron Corporation)
Last update: 19 hours ago1.65
0.02 (1.23%)
| Previous Close | 1.63 |
| Open | 1.63 |
| Volume | 12,595,511 |
| Avg. Volume (3M) | 9,613,916 |
| Market Cap | 1,053,286,144 |
| Price / Sales | 6.03 |
| Price / Book | 4.26 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2026 |
| Profit Margin | -119.54% |
| Operating Margin (TTM) | -42.18% |
| Diluted EPS (TTM) | -0.210 |
| Quarterly Revenue Growth (YOY) | 12,927.30% |
| Total Debt/Equity (MRQ) | 45.40% |
| Current Ratio (MRQ) | 7.86 |
| Operating Cash Flow (TTM) | -204.34 M |
| Levered Free Cash Flow (TTM) | -142.38 M |
| Return on Assets (TTM) | -16.07% |
| Return on Equity (TTM) | -45.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Geron Corporation | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.38 |
|
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.09% |
| % Held by Institutions | 81.26% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Geron Corporation Provides 2026 Financial Guidance |
| 18 Dec 2025 | Announcement | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 11 Dec 2025 | Announcement | Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation |
| 08 Dec 2025 | Announcement | Geron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDS |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |